India's generic drugmakers bursting with impatience
Medicines worth $40bn in the US and $25bn in Europe stand to lose patent protection in the next two years, but impatient Indian generic drugmakers are pushing to accelerate the pace through patent
Medicines worth $40bn in the US and $25bn in Europe stand to lose patent protection in the next two years, but impatient Indian generic drugmakers are pushing to accelerate the pace through patent